How should esophageal dysmotility with diminished primary and secondary peristaltic waves be managed?

Management of Esophageal Dysmotility with Diminished Primary and Secondary Peristaltic Waves

Perform high-resolution esophageal manometry to definitively characterize the dysmotility pattern, then initiate twice-daily proton pump inhibitor therapy as first-line treatment while addressing the underlying cause if identified.

Diagnostic Approach

The first critical step is obtaining high-resolution manometry (HRM) to precisely define the motility disorder 1. This is essential because diminished peristalsis can represent several distinct conditions:

• Ineffective esophageal motility (IEM) - characterized by distal esophageal amplitude <30 mmHg or >30% simultaneous waves
• Absent contractility - complete aperistalsis
• Nonspecific esophageal motility disorder (NSEMD) - intermediate dysfunction

Key diagnostic sequence:

1. If dysphagia is present: Perform endoscopy with biopsies first to exclude structural lesions, eosinophilic esophagitis (minimum 5 biopsies), metaplasia, or malignancy 1

2. If symptoms persist despite empirical twice-daily PPI therapy and endoscopy is normal: Proceed to manometry 1

3. If manometry shows no major motor disorder: Consider ambulatory pH-impedance monitoring (off PPI for 7 days) to assess acid exposure and symptom correlation 1

Identify Secondary Causes

Before treating as primary dysmotility, actively screen for:

• Systemic sclerosis, mixed connective tissue disease, SLE, or Sjögren's disease - these commonly cause severe esophageal hypomotility with incompetent lower esophageal sphincter 2
• Recent COVID-19 infection or Chagas disease risk - can cause secondary achalasia-like patterns 2
• Eosinophilic esophagitis - may present with dysmotility 2
• Crohn's disease - rarely involves esophagus with inflammatory changes 2

If systemic sclerosis is suspected, refer to rheumatology for serologic testing and comprehensive evaluation 2.

Medical Management

First-Line Therapy: Proton Pump Inhibitors

Initiate twice-daily PPI therapy regardless of whether reflux symptoms are prominent 1, 3. The rationale is multifactorial:

• Patients with abnormal peristalsis have more severe reflux and slower acid clearance 4
• Secondary peristalsis is significantly impaired in GERD patients (only 7.1% of air boluses trigger normal secondary peristalsis vs 32% in controls) 5
• Primary peristaltic waves are the dominant mechanism for refluxate clearance (48.4% of episodes), and when these are diminished, acid exposure worsens 6

Dosing: Standard-dose PPI twice daily (e.g., omeprazole 20mg BID, esomeprazole 40mg BID). Expert consensus supports twice-daily dosing despite most trial data being from once-daily studies 1.

Prokinetic Agents

Consider adding prokinetic therapy for symptomatic motility disturbances, particularly if bloating, early satiety, or gastroparesis symptoms coexist 7, 3:

• Prucalopride (5-HT4 agonist): Effective for constipation and small bowel dysmotility without cardiac risks 7
• Domperidone: Shown in RCT to improve GERD symptoms in SSc patients on high-dose PPI 3
• Erythromycin 900mg/day: Useful if absent/impaired antroduodenal migrating complexes, but subject to tachyphylaxis 7
• Azithromycin: May be more effective than erythromycin for small bowel dysmotility 7

For systemic sclerosis specifically: Octreotide 50-100μg subcutaneously once or twice daily can be dramatically beneficial when other treatments fail, with effects apparent within 48 hours 7. May be more effective when combined with erythromycin.

Adjunctive Measures

• Dietary modifications: Small, frequent meals; avoid late-night eating; remain upright 2-3 hours post-meal
• Avoid medications that worsen motility: Calcium channel blockers, nitrates, anticholinergics, opioids
• If opioid-related: Consider naloxone 1.6mg subcutaneously daily or methylnaltrexone on alternate days 7

Common Pitfalls

1. Do not assume all dysmotility is primary: Always screen for systemic sclerosis and other connective tissue diseases, especially in women aged 30-50 2

2. Do not withhold PPI therapy based on absence of heartburn: Dysmotility itself predisposes to reflux complications including strictures and Barrett's esophagus 3

3. Do not use H2-receptor antagonists instead of PPIs: They are ineffective for reducing stricture recurrence and inferior for symptom control 8

4. Healing of esophagitis does not reverse dysmotility: Abnormalities of secondary peristalsis persist even after mucosal healing 5

Surgical Considerations

If considering anti-reflux surgery:

• Manometry is mandatory to rule out achalasia and major motor disorders (which are contraindications) 9
• IEM and weak peristalsis are NOT contraindications to fundoplication - preoperative peristaltic amplitude does not predict postoperative dysphagia 9, 10
• In complete aperistalsis (scleroderma-like esophagus), partial fundoplication may be offered in highly selected patients with prominent reflux, or consider Roux-en-Y gastric bypass as alternative 10

Monitoring

• Regular blood pressure monitoring if glucocorticoids are used (risk of scleroderma renal crisis) 3
• Repeat endoscopy if alarm symptoms develop (dysphagia, weight loss) or inadequate response to therapy 1
• Long-term PPI safety considerations: Be aware of potential risks with prolonged use, but benefits typically outweigh risks for preventing strictures and ulcers 3